Drug Patents owned by Chiesi
1. Drug name - CARDENE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
| US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(5 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(5 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 25MG/10ML (2.5MG/ML) | INJECTABLE;INJECTION | Discontinued |
| 40MG/200ML (0.2MG/ML) | INJECTABLE;INTRAVENOUS | Discontinued |
| 20MG/200ML (0.1MG/ML) | INJECTABLE;INTRAVENOUS | Prescription |
2. Drug name - CLEVIPREX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(9 years from now) | |
| US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(9 years from now) | |
| US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(9 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 25MG/50ML (0.5MG/ML) | EMULSION;INTRAVENOUS | Prescription |
| 50MG/100ML (0.5MG/ML) | EMULSION;INTRAVENOUS | Prescription |
| 125MG/250ML (0.5MG/ML) | EMULSION;INTRAVENOUS | Discontinued |
3. Drug name - FERRIPROX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(7 years from now) | |
| US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(16 years from now) | |
| US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(16 years from now) | |
| US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(16 years from now) | |
Drugs and Companies using DEFERIPRONE ingredient
Treatment: Method of treating transfusional iron overload
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 80MG/ML | SOLUTION;ORAL | Discontinued |
| 100MG/ML | SOLUTION;ORAL | Prescription |
4. Drug name - KENGREAL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6130208 | CHIESI | Formulation containing a nucleotide analogue |
Jun, 2023
(8 months from now) | |
| US9925265 | CHIESI | Methods of treating or preventing stent thrombosis |
May, 2029
(6 years from now) | |
| US9427448 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Nov, 2030
(8 years from now) | |
| US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(10 years from now) | |
| US9295687 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
| US10039780 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
| US9439921 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
| US9700575 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
Drugs and Companies using CANGRELOR ingredient
Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor; Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion; Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci; Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.